![Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha](https://static.seekingalpha.com/uploads/2019/5/49102172_15591559956443_rId6.png)
Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha
![PUMA® - PUMA achieved the highest Sales and EBIT in its history due to continued Brand Momentum and operational Flexibility PUMA® - PUMA achieved the highest Sales and EBIT in its history due to continued Brand Momentum and operational Flexibility](https://cdn.about.puma.com/-/media/images/newsroom/corporate-news/2022/og.jpg?rev=7694de70719c4216b08adb2136ab94ee)
PUMA® - PUMA achieved the highest Sales and EBIT in its history due to continued Brand Momentum and operational Flexibility
![PUMA® - PUMA achieved the highest Sales and EBIT in its history due to continued Brand Momentum and operational Flexibility PUMA® - PUMA achieved the highest Sales and EBIT in its history due to continued Brand Momentum and operational Flexibility](https://cdn.about.puma.com/-/media/images/newsroom/corporate-news/2022/grafik-q4-2020.jpg?as=1&h=608&iar=1&w=1080&rev=f325ec44bdcd48a29eae7cff371c5db8&hash=2B9DBBFFFC3CDAC4B62234181E92A48A)